Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab Combination Presented at the 2026 European Hematology Association Congress Plenary Showed Prolonged Progression Free Survival
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
Incyte's Pivotal frontMIND Trial Showed Tafasitamab Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
Incyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association 2026 Congress
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® Cream in Adults with Moderate Atopic Dermatitis
Incyte Announces FDA Approval of Jakafi XR Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology Annual Meeting
